Menu
Logo

Uptravi dosing vs Adverse events

REFERENCES

1. Uptravi Summary of Product Characteristics. Actelion Pharmaceuticals Ltd; 2017. https://www.ema.europa.eu/en/documents/product-information/uptravi-epar-product-information_en.pdf . Accessed September 2020.

2. Sitbon 0, Channick R, Chin KM, et al; for the GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015; 373(26):2522-2533.

CP-266811